Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Free Report) rose 10% during trading on Thursday . The company traded as high as $1.21 and last traded at $1.21. Approximately 179,099 shares were traded during trading, a decline of 57% from the average daily volume of 414,672 shares. The stock had previously closed at $1.10.
Dermata Therapeutics Price Performance
The firm has a market cap of $2.47 million, a price-to-earnings ratio of -0.07 and a beta of 0.65. The business’s 50-day moving average price is $1.24 and its two-hundred day moving average price is $1.36.
About Dermata Therapeutics
Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
Recommended Stories
- Five stocks we like better than Dermata Therapeutics
- Industrial Products Stocks Investing
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- How to start investing in penny stocks
- 3 Stocks to Buy While Others Stay on the Sidelines
- Manufacturing Stocks Investing
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
